Introduction: Emergence agitation is the abnormal mental status that develops as the result of anesthesia administration during the transition from unconsciousness to complete wakefulness. It occurs in all age groups but is more common in pediatrics. If emergence agitation is not prevented, it can lead to serious life-threatening phenomena. Thus, preventing the occurrence of emergence agitation would reduce the unwanted side effects and makes emergence smooth. Objective: This study aimed to assess the effectiveness of propofol in the mitigation of emergence agitation among pediatric patients undergone elective surgery under general anesthesia at Jimma University Medical Center. Methods: A prospective observational cohort study design was conducted from August, 1/2022 to October 30/ 2022 among pediatric patients aged 2-14 years who underwent elective surgery under general anesthesia. A total of 76 patients were enrolled in the study in two groups (propofol and non-propofol) with 38 patients in each. Data were collected from all study populations who fulfilled the inclusion criteria. The incidence and severity of EA were assessed by the pediatric anesthesia emergence delirium scale in the post-anesthesia care unit at different time intervals. The presence of emergence agitation was considered when the pediatric anesthesia emergence delirium scale was ≥ 12 and severity was classified as no agitation [0-11] , agitation [12-15] , severe agitation [≥ 16]. The data were checked manually for completeness then entered and cleaned using Epi Info, version 7, and exported to Statistical Package for Social Sciences (SPSS) software, version 26.0 for analysis. Normality was tested using the shapiro-wilk test, and histogram. A comparison of numerical variables between the study groups was done using an independent sample t-test. Chi-square/Fischer exact test was used to compare categorical variables and presented as numbers and percentages. The incidence of EA was also presented in confidence interval and relative risk. A p-value less than 0.05 was taken as statically significant. Result: The overall incidence of EA in both groups was 48.7% (37%−60.4%). The incidence of EA in the propofol group and non-group was 34.2% (19.6%−51.4%) vs 63.2% (46%−78.2%) respectively p=0.012, which means that EA was significantly decreased in the propofol group in comparison to the non-propofol group. There was a significant reduction in the severity of EA at time intervals of 5th and 15th minutes; P =0.012 vs 0.029 respectively. However, there was no significant difference in the severity of EA at the 30th minute between the groups; P=0.08. The relative risk of EA in the propofol group was 0.54; 95% confidence interval (CI) 0.3270.896. This showed propofol group had less risk of emergence agitation in comparison to the non-propofol group. Conclusion and Recommendation: The administration prophylactic propofol at the end of surgery is vital in reducing both the incidence and severity of emergence agitation and makes recovery smooth. Thus, we recommend the routine prophylactic propofol at the end of surgery to reduce the incidence and severity of postoperative emergence agitation in pediatric patients. Key Words: Propofol; Emergency Agitation; Pediatrics surgery; General anesthesia

The authors have declared no competing interest.

This study did not receive any fundin

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Jimma University, institute of health, faculty of medical sciences, institute review board granted ethical approval for this study on May 29, 2022 with protocol number JUIH/IRB/81/22, Jimma, Ethiopia.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript